With over 25 years of dedicated service to the life sciences industry, Cooley Godward Kronish has built one of the most integrated and comprehensive life sciences legal practices in the country. We have represented nearly 30 percent of the companies on the NASDAQ Biotechnology and BioCentury 100™ Indices and more than half of the companies on the AMEX Biotech Index. Today, we represent over 500 life sciences companies, both public and private, here in the U.S. and internationally, in nearly all aspects of their business. Our deep domain expertise also enables us to effectively and efficiently represent many venture capital clients in their investments in life sciences companies, as well as lending institutions and investment banks servicing those companies.
We bring to our client relationships a unique combination of innovative legal advice, deep industry knowledge and practical understanding of our clients’ business needs in today’s changing and challenging environment. Our track record speaks for itself:
- Ranked first among U.S. and California law firms for the number of attorneys included in the Biotechnology Law category of The Best Lawyers in America, 2006 edition
- Ranked #1 among all law firms in the representation of issuer-side life sciences companies in their public offerings since 2003 (IPO Vital Signs)
- Handled nearly 25% of all life sciences IPOs filed in 2004 – 2006
- Listed as the #1 law firm in the U.S. in representing private, venture-backed biopharmaceutical companies from 2002 to 2006 (VentureSource)
- Listed as the # 1 for the number of life sciences company clients securing capital from 2004 – 2006
- Closed more than 40 M&A deals for life sciences companies since 2000, with a total deal value in excess of $10 billion
Our attorneys have deep expertise across all aspects of life sciences technologies, including genomics, proteomics, drug discovery tools, vaccines, screening assays and methods, biological and small organic therapeutic compounds and uses. We have particular expertise in “cross-over” matters involving bioinformatic and other IT-implemented inventions.
Related practices
